آگوست 10, 2021

Description: Kio Medical has developed this app to quantify features related to the heterogeneity of the brain tissue and obtain texture parameters. Those texture parameters can be considered as indicators of tumor aggressiveness and help in brain tumor staging and phenotyping of pathological tissues.   Disease: Solid tumors Glioblastoma Related Contents:

Description: Kio Medical has developed this app to automatically obtain the T2 mapping of tumors and depict changes and abnormalities with AI segmentation. The analysis of T2 mapping provides imaging biomarkers for the assessment and monitoring of solid tumors, such as prostate cancer, rectal cancer and liver cancer, among others.       Disease: Solid tumors Prostate cancer Rectal cancer Endometrial cancer Liver cancer Related Contents:

Description: Kio Medical has developed a software aimed at examining intrinsic networks in the brain while no task is performed to estimate correlations between brain regions. It measures spontaneous low-frequency fluctuations in the BOLD signal to investigate the functional architecture of the brain. One can either identify regions that have a close functional relationship with a given (seed) region, identify strongly connected regions, or perform a hypothesis-free independent component analysis across the whole brain. Its use in presurgical planning for

Description: Kio Medical’s software automatically performs intra-voxel incoherent motion (IVIM) analysis to detect changes in the microstructure of tissues to assess cancer processes in clinical practice and research. The tool allows the differentiation of pure diffusion changes due to variations in the vascular component and offers additional information complementary to conventional ADC results. This is useful for the characterization of tumoral processes to improve early detection, diagnosis, treatment response evaluation and follow-up of patients with gliomas, meningiomas and lymphomas. Disease:

Description: Kio Medical has developed an app to quantify the volumes of the right and left hippocampus, frontal lobes and temporal lobes, to help assess disease diagnosis and progression. The obtained values are framed in a normative database to be compared with healthy subjects of the same age and gender. This software can be used to diagnose and monitor patients with Alzheimer’s disease, mild cognitive impairment and frontotemporal dementia.   Disease: Alzheimer’s disease Mild cognitive impairment (MCI) Frontotemporal dementia Related

Description: Kio Medical has developed a software that relies on the susceptibility induced signal loss on T2*-weighted sequences which results from a bolus of gadoliniumbased contrast passing through a capillary bed. The most commonly calculated parameters in this software are rCBV, rCBF, and MTT as dynamic susceptibility contrast-enhanced MR perfusion, still abbreviated to DSC. This software also noninvasively characterizes tumor biology allowing for the diagnosis and therapeutic monitoring of glioma. Disease: ❖ Solid tumor ❖ Prostate cancer ❖ Rectal cancer

Description: Kio Medical has developed a software to automatically extract vascular-based imaging biomarkers to detect changes associated with increased tumor neoangiogenesis activity and aggressiveness. It used in the software helps detect neoplasms and quantifies tumor neoangiogenesis to stage cancer aggressiveness. This tool is useful for the characterization of tumoral processes in the early detection, diagnosis, treatment response evaluation and follow-up of patients with cancer.     Disease: Solid tumor Prostate cancer Rectal cancer Endometrial cancer Liver cancer Related Contents:

Description: Kio Medical’s software enables to automatically calculate the apparent diffusion coefficient (ADC) to quantify the diffusion of water molecules in tissues. It provides information on the cellular and microstructural organization of tissues and highlights the relationship between pathological changes and the diffusion of water molecules. This is useful for the characterization of tumoral processes to improve early detection, diagnosis, treatment response evaluation and follow-up of patients with gliomas, meningiomas and lymphomas as well as ischemic injuries. Disease: Glioma Meningiomas